- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
UPDATED May 13, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
77 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
ITCI | US$66.32 | -6.6% | 2.2% | US$7.0b | US$90.60 | PS13.6x | E61.0% | n/a | ||
TGTX | US$17.32 | 4.9% | -44.4% | US$2.5b | US$31.50 | PE60.2x | E48.0% | n/a | ||
RYTM | US$40.20 | -8.4% | 138.0% | US$2.5b | US$57.22 | PS26.7x | E65.6% | n/a | ||
MIRM | US$24.78 | -6.1% | -4.8% | US$1.2b | US$47.55 | PS5.2x | E71.3% | n/a | ||
GERN | US$3.74 | 0.3% | 23.0% | US$2.2b | US$6.07 | PS4266x | E64.9% | n/a | ||
SPPI | US$1.03 | 5.3% | 17.0% | US$209.9m | US$1.26 | PS8.2x | E67.3% | n/a | ||
ARCT | US$28.72 | 5.1% | -6.2% | US$773.5m | US$72.29 | PS6.2x | E65.8% | n/a | ||
RCEL | US$8.35 | -6.2% | -33.9% | US$215.4m | US$25.90 | PS4.3x | E62.0% | n/a | ||
FOLD | US$9.04 | -12.6% | -19.3% | US$2.7b | US$18.00 | PS6.3x | E60.4% | n/a | ||
AUPH | US$5.02 | -2.7% | -53.9% | US$716.2m | US$10.14 | PS3.7x | E52.0% | n/a | ||
IOVA | US$10.88 | -21.6% | 38.8% | US$3.0b | US$26.00 | PS1599x | E66.3% | n/a | ||
ACAD | US$15.18 | -10.7% | -31.4% | US$2.5b | US$27.16 | PS3.1x | E40.8% | n/a | ||
LEGN | US$42.97 | -5.1% | -41.2% | US$7.8b | US$86.27 | PS22.8x | E62.1% | n/a | ||
LQDA | US$12.14 | -4.3% | 64.1% | US$927.3m | US$25.14 | PS53x | E60.4% | n/a | ||
KRTX | US$329.83 | 3.3% | 80.7% | US$12.6b | US$326.92 | PS19238.9x | E60.1% | n/a | ||
DVAX | US$11.03 | -5.2% | -3.8% | US$1.4b | US$24.67 | PE156.6x | E42.8% | n/a | ||
EXEL | US$21.27 | -2.9% | 9.1% | US$6.2b | US$26.76 | PE30.2x | E24.2% | n/a | ||
APLS | US$43.01 | -11.9% | -51.2% | US$5.2b | US$80.38 | PS10x | E60.0% | n/a | ||
ZLAB | US$21.52 | 27.3% | -36.0% | US$2.1b | US$51.21 | PS7.3x | E65.1% | n/a | ||
AVDL | US$16.81 | -9.7% | n/a | US$1.5b | US$23.65 | PS27.6x | E61.3% | n/a | ||
CPRX | US$16.22 | 8.2% | 23.4% | US$1.9b | US$27.29 | PE29.4x | E20.0% | n/a | ||
TEVA | US$16.88 | 20.1% | 109.2% | US$19.1b | US$17.34 | PS1.2x | E40.4% | 0% | ||
FRLN | US$6.48 | -0.2% | -21.7% | US$28.3m | US$8.25 | PS45.4x | E60.7% | n/a | ||
BPMC | US$108.05 | 1.7% | 96.0% | US$6.8b | US$118.13 | PS24x | E66.4% | n/a |